Lantern Pharma Inc.
$2.76
▲
14.08%
2026-04-21 07:59:00
www.lanternpharma.com
NCM: LTRN
Explore Lantern Pharma Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$27.91 M
Current Price
$2.76
52W High / Low
$5.74 / $1.11
Stock P/E
—
Book Value
$0.58
Dividend Yield
—
ROCE
-275.14%
ROE
-1.24%
Face Value
—
EPS
$-1.57
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
16
Beta
1.75
Debt / Equity
1.2
Current Ratio
2.4
Quick Ratio
2.4
Forward P/E
-0.98
Price / Sales
—
Enterprise Value
$12.13 M
EV / EBITDA
-0.68
EV / Revenue
—
Rating
Strong Buy
Target Price
$20
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Ernexa Therapeutics Inc. | $0.19 | — | $5.87 M | 0.34% | -342.48% | -6.87% | $4.05 / $0.18 | $0.31 |
| 2. | MeiraGTx Holdings plc | $10.53 | — | $857.63 M | — | -86.95% | -3.68% | $11.85 / $4.55 | $-0.07 |
| 3. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 4. | Alaunos Therapeutics, Inc. | $2.84 | — | $6.71 M | — | -233.25% | -1.98% | $6.2 / $1.67 | $1.27 |
| 5. | Celularity Inc. | $1.24 | — | $35.47 M | — | -48.8% | -232.51% | $4.35 / $1.01 | $-0.71 |
| 6. | NextCure, Inc. | $11.7 | — | $41.66 M | — | -145.43% | -1.11% | $15.74 / $3.85 | $9.97 |
| 7. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.2 M | -4.35 M | -4.65 M | -4.77 M | -5.9 M | — |
| Net Profit | -4.07 M | -4.18 M | -4.33 M | -4.54 M | -5.88 M | — |
| EPS in Rs | -0.36 | -0.37 | -0.38 | -0.4 | -0.52 | -0.42 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -17.98 M | -22.22 M | -17.88 M | -14.43 M |
| Net Profit | -17.12 M | -20.78 M | -15.96 M | -14.26 M |
| EPS in Rs | -1.52 | -1.85 | -1.42 | -1.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 11.04 M | 25.57 M | 43.65 M | 58.84 M |
| Total Liabilities | 4.5 M | 4.38 M | 2.74 M | 2.8 M |
| Equity | 6.53 M | 21.19 M | 40.91 M | 56.04 M |
| Current Assets | 10.8 M | 25.25 M | 43.34 M | 58.72 M |
| Current Liabilities | 4.5 M | 4.33 M | 2.68 M | 2.8 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -15.68 M | -17.81 M | -14.35 M | -12.77 M |
| Investing CF | 11.06 M | 3.37 M | -0.93 M | 0.18 M |
| Financing CF | 1.5 M | 0.07 M | -0.5 M | -2.18 M |
| Free CF | -15.68 M | -17.83 M | -14.37 M | -12.8 M |
| Capex | -0 M | -0.01 M | -0.02 M | -0.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -30.2% | -11.93% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.